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Abstract 
Stroke is the third most common cause of death in the United States and it is the leading cause of disability. Early 
diagnosis and immediate therapeutic interventions are important factors to reduce the extent of brain tissue damage and the risk of 
stroke-related death. A rapid blood test that can confirm the clinical or imaging diagnosis or that can add to the stratification of the 
risk would be very useful. Such a test has to be validated in large studies and has to be based on a simple and low-cost technology. 
Many biological markers were tested for their ability to serve as “would-be” stroke biological markers; some of them appear to have a 
place in the diagnostic work-up of stroke patients. These molecules include Glial Fibrillary Acidic Protein (GFAP), the N-methyl-D-
aspartate receptor (NMDA), APO C-III, APO C-I, PARK7, nucleoside diphosphate kinase A (NDKA), S100B, B-type neurotrophic 
growth factor, von Willebrand factor, matrix metalloproteinase-9, and monocyte chemotactic protein-1. There are obvious limitations 
to this study, among them the fact that disability does not necessarily correlate with the amount of cerebral tissue lost (the site of 
stroke may be more important) and the role of the blood-brain barrier in delaying the release of the neuronal proteins in the blood 
stream. Further studies are awaited to confirm the role of these molecules in the management of acute stroke patients. 
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Introduction 
Stroke is the third most common cause of death 
in the United States and the leading cause of disability 
(physical and mental). The survivors of such an event are 
confronted with physical and mental handicaps (5 years 
from the acute event up to 25% of stroke patients develop 
vascular dementia), with a decisive impact on life 
expectancy, quality of life and the cost supported by the 
society. The health-care expenditures resulting from a 
stroke are estimated to be $140,000 per patient [1]. 
Chronic nursing costs can be reduced by limiting the 
number of sequelae by a more precocious diagnosis 
during the acute period, thus allowing initiation of a 
specific therapy even before the patient reaches the 
stroke unit, and by adaptation of the therapy to the risk of 
each patient. 
At the moment, the diagnosis of stroke is based 
on a stroke clinician’s examination  of the patient, 
supplemented by the results of brain imaging. However, in 
people who are suspected of having a stroke, the clinical 
assessment within the first hours is not  always 
straightforward. Either patients with acute stroke cannot 
be assessed by a stroke specialist, or the interpretation of 
the brain  images can be difficult, as computerized 
tomography (CT) images are often normal after the onset 
of ischemia and may remain normal in patients with mild 
ischemic strokes. MRI is still not 100% sensitive or 
specific and may not be feasible in acutely ill patients 
because they are restless, they have a contraindication to 
MRI, or MRI is not immediately available. In the case of a 
hemorrhagic stroke, the early onset of a specific therapy 
may limit the extent of brain damage in the first hours. 
Thus, sending patients directly to specialized units 
(neurosurgery, stroke unit) may improve their prognoses 
[2]. 
A rapid blood test that can confirm the clinical or 
imaging diagnosis or can add to the stratification of the 
risk would be very useful. Such a test must be validated 
by large studies and must be based on a simple and low-
cost technology. There are obvious limitations for such a 
study, among them the fact that disability does not 
necessarily correlate with the amount of cerebral tissue 
lost (the site of stroke may be more important) and the 
role of the blood-brain barrier in delaying the release of 
the neuronal proteins in the blood stream. 
The ability of many biological markers to serve 
as “would-be” stroke biological markers was studied; 
some of these molecules appear to have a place in the 
diagnostic work-up of the stroke patient. These molecules Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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include Glial Fibrillary Acidic Protein (GFAP), the N-
methyl-D-aspartate receptor (NMDA), APO C-III, APO C-I, 
PARK7, nucleoside diphosphate kinase A (NDKA), and 
S100B [3]. All of these molecules appear to have 
significance for ischemic stroke; GFAP, S100B and APO 
C-III may also be used as potential plasmatic markers to 
distinguish between ischemic and hemorrhagic stroke. 
Reynolds developed a panel of five proteins (S100B, B-
type neurotrophic growth factor, von Willebrand factor, 
matrix metalloproteinase-9, and monocyte chemotactic 
protein-1) that appears to be capable of diagnosing a 
stroke with sensitivity and specificity above 90% [4]. 
 
Glial Fibrillary Acidic Protein (GFAP) 
GFAP is a brain-specific intermediate filament 
protein found in astrocytes. It was recently identified as a 
biomarker indicative of intracerebral hemorrhage in the 
acute phase of stroke. Foerch prospectively included 93 
patients with ischemic stroke (IS) and 42 patients with 
intracerebral hemorrhage (ICH) within 6 hours of 
symptom onset. GFAP was detectable in the serum in 
81% of ICH patients but only in 5% of IS patients. The 
mean GFAP serum concentration was significantly higher 
in patients with ICH. A cutoff point of 2.9 ng/L was found 
to provide a sensitivity of 79% and a specificity of 98% for 
the differentiation of ICH from IS. The more sudden 
disruption of astroglial cells and the blood–brain barrier 
(BBB) in ICH may be responsible for the rapid occurrence 
of GFAP in the serum, in comparison to a more delayed 
release of astroglial proteins in IS [5]. 
 
S100B 
S100B is a Ca2+-binding protein found in glial 
cells in the central nervous system. The concentration of 
this protein increases in the plasma after brain damage 
due to IS; high blood S100B concentrations are 
associated with infarct size, outcome and neurovascular 
status on admission [6]. It also can be used as a marker 
of success after thrombolysis with a tissue plasminogen 
activator. 
More recent studies have found increased 
S100B plasma levels after acute spontaneous ICH in 
association with worse early and late clinical evolution. 
Moreover, S100B is considered a relevant diagnostic tool 
in the perinatal context due to its ability to predict 
intraventricular hemorrhage in preterm  and asphyxiated 
full-term infants when other clinical or radiological 
assessments are still silent [7, 8]. 
 
APO C-III 
ApoC-III is present in normal plasma at 0.1 g/L 
and is mainly found in VLDL but is also found in HDL and 
LDL particles. It is mainly expressed by the liver. ApoC-III 
is known to inhibit lipoprotein lipase present on the 
surface of vascular endothelial cells. A high ApoC-III 
concentration in lipoproteins is a prominent component of 
atherogenic dyslipidemia and explains the risk of coronary 
heart disease associated with high triglyceride levels. 
APO C-III is overexpressed in acute IS patients relative to 
acute ICH patients [9]. 
Conclusion 
Early diagnosis and immediate therapeutic 
interventions are important factors to reduce the extent of 
brain tissue damage and the risk of stroke-related death. 
Currently, the diagnosis of stroke relies on neurological 
assessment of the patient and neuro-imaging techniques 
including computed tomography and/or magnetic 
resonance imaging. An early diagnostic marker of stroke, 
ideally capable of discriminating ischemic stroke from 
hemorrhagic stroke, would considerably improve patient 
management. There are some biological markers that 
have been studied as predictors of the type of stroke, 
including GFAP, NMDA, S100B, and Apo C-III. Further 
studies are awaited to confirm the role of these markers in 
the management of patients with acute stroke. 
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